Mustang Bio ventures into gene therapy, licensing 'bubble boy disease' treatment from St. Jude
When Mustang Bio $MBIO inked the lease deal for its Worcester, MA manufacturing facility last year, CEO Manny Litchman said a more cost effective manufacturing approach would lend a competitive edge to their early-stage CAR-T programs. As it turns out, gene therapy will also be part of that game plan.
Licensing from St. Jude Children’s Research Hospital in Memphis, Mustang adds an ex vivo lentiviral gene therapy to for one form of “bubble boy disease” to its pipeline, which has up till now been stocked with cancer-fighting cell therapies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.